Genitourinary Cancers Symposium (ASCO GU)

Treatment of EBRT with or without STAD for 6 months demonstrated an improvement in prostate cancer-specific survival in intermediate-risk prostate cancer.

A low composite gene expression score was associated with improved outcomes in patients with mCRPC who received bavdegalutamide.

G-CSF use and docetaxel dose modifications allowed patients with mHSPC to receive efficacious doses of docetaxel in the ARASENS trial.

Adding Lu-PSMA-617 to enzalutamide significantly improved overall survival and quality of life in metastatic castration-resistant prostate cancer.

Talazoparib plus enzalutamide demonstrates improved overall survival in metastatic castration-resistant prostate cancer.

Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.

Tinengotinib elicited responses with a manageable safety profile in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Real-world recurrence and prognosis was determined through the identification of morphologic RCC types and tumor stages.

Subcutaneous nivolumab coformulated with rHuPH20 demonstrated noninferiority of PK exposures vs intravenous nivolumab in metastatic ccRCC.

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Treatment with adjuvant pembrolizumab significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Frontline pembrolizumab plus lenvatinib continues to show benefit vs historical controls in advanced non–clear cell renal cell carcinoma.

Lenvatinib/pembrolizumab shows a trend of improved PFS and overall response rate vs standard immunotherapies in advanced renal cell carcinoma.

Belzutifan treatment led to improved quality of life outcomes vs treatment with everolimus in patients with advanced renal cell carcinoma.

Adjuvant pembrolizumab generated a disease-free survival benefit vs observation in patients with muscle-invasive and locally advanced urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab showed consistent overall survival and progression-free survival benefit in all patients enrolled in EV-302.

Pembrolizumab plus cabozantinib was efficacious in the first-line treatment of patients with cisplatin-ineligible urothelial carcinoma.

Andrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.

Assessment of urinary MRD status identified and enabled quantification of molecular responses with nadofaragene firadenovec in BCG-unresponsive NMIBC.

Amanda Nizam, MD, discusses findings from the UNITE study of enfortumab vedotin after maintenance avelumab in patients with advanced urothelial carcinoma.

Dalia Kaakour, MD, discusses real-world findings on genomic testing patterns in patients with prostate cancer.

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Patients with HRR gene–mutated mCRPC treated with olaparib have an unmet need for early and consistent genetic testing to optimize treatment outcomes.

Olaparib plus abiraterone acetate delayed disease progression and improved outcomes in patients with BRCA-, ATM- and CDK12-mutated mCRPC.

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.

Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.